[go: up one dir, main page]

WO2002009757A1 - Preventives or remedies for obesity or fatty liver - Google Patents

Preventives or remedies for obesity or fatty liver Download PDF

Info

Publication number
WO2002009757A1
WO2002009757A1 PCT/JP2001/006532 JP0106532W WO0209757A1 WO 2002009757 A1 WO2002009757 A1 WO 2002009757A1 JP 0106532 W JP0106532 W JP 0106532W WO 0209757 A1 WO0209757 A1 WO 0209757A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty liver
obesity
preventives
remedies
resorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/006532
Other languages
English (en)
French (fr)
Inventor
Teruo Shiomi
Seijiro Hara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to CA002417492A priority Critical patent/CA2417492A1/en
Priority to EP01984401A priority patent/EP1306094A4/en
Priority to KR10-2003-7001367A priority patent/KR20030036658A/ko
Priority to AU2002224596A priority patent/AU2002224596A1/en
Publication of WO2002009757A1 publication Critical patent/WO2002009757A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2001/006532 2000-08-01 2001-07-30 Preventives or remedies for obesity or fatty liver Ceased WO2002009757A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002417492A CA2417492A1 (en) 2000-08-01 2001-07-30 Preventives or remedies for obesity or fatty liver
EP01984401A EP1306094A4 (en) 2000-08-01 2001-07-30 PROPHYLAXIS OR THERAPY FOR GASOLIBILITY OR FATIGUE
KR10-2003-7001367A KR20030036658A (ko) 2000-08-01 2001-07-30 비만 또는 지방간의 예방 또는 치료제
AU2002224596A AU2002224596A1 (en) 2000-08-01 2001-07-30 Preventives or remedies for obesity or fatty liver

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000233072 2000-08-01
JP2000-233072 2000-08-01

Publications (1)

Publication Number Publication Date
WO2002009757A1 true WO2002009757A1 (en) 2002-02-07

Family

ID=18725654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/006532 Ceased WO2002009757A1 (en) 2000-08-01 2001-07-30 Preventives or remedies for obesity or fatty liver

Country Status (7)

Country Link
US (1) US20030153513A1 (ja)
EP (2) EP1306094A4 (ja)
KR (1) KR20030036658A (ja)
CN (1) CN1466465A (ja)
AU (1) AU2002224596A1 (ja)
CA (1) CA2417492A1 (ja)
WO (1) WO2002009757A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009120597A (ja) * 2007-10-24 2009-06-04 Mitsubishi Tanabe Pharma Corp 非アルコール性脂肪肝炎の治療および／または予防薬
WO2009096455A1 (ja) * 2008-01-31 2009-08-06 Astellas Pharma Inc. 脂肪性肝疾患の治療用医薬組成物
WO2010038796A1 (ja) * 2008-09-30 2010-04-08 持田製薬株式会社 Ｃ型肝炎治療剤
JP2015150544A (ja) * 2014-02-19 2015-08-24 国立大学法人神戸大学 表面処理剤、表面処理ポリアミド逆浸透膜及びその製造方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060109926A (ko) * 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
AU2006249348B2 (en) * 2005-05-26 2012-05-24 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
JP2012509891A (ja) * 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
CN106176800B (zh) * 2016-07-11 2019-12-06 韩源平 多聚阳离子树脂的制药应用
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
JP7168660B2 (ja) 2017-06-05 2022-11-09 バイキング・セラピューティクス・インコーポレイテッド 線維症の処置のための組成物
KR101844184B1 (ko) * 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 아미노알킬벤조티아제핀 유도체의 용도
MX2020009843A (es) 2018-03-22 2020-12-11 Viking Therapeutics Inc Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06279278A (ja) * 1993-03-30 1994-10-04 Snow Brand Milk Prod Co Ltd 脂肪肝抑制剤
JPH09241206A (ja) * 1996-03-01 1997-09-16 Shionogi & Co Ltd リグナン系化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1209138A (en) * 1969-06-13 1970-10-21 Pharma Chemie IMPROVEMENTS IN OR RELATING TO A NEW alpha-NAPHTHOXY-ISOBUTYRIC ACID DERIVATIVE, PROCESS FOR ITS PREPARATION AND THERAPEUTICAL COMPOSITION CONTAINING SAME
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
DE69228262D1 (de) * 1991-10-17 1999-03-04 Shionogi & Co Verfahren zum Herstellen von Lignin-Analoga und Ausgangsprodukte dafür
WO1998041216A1 (en) * 1997-03-17 1998-09-24 Tam Yun K Composition for prevention of hepatic steatosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06279278A (ja) * 1993-03-30 1994-10-04 Snow Brand Milk Prod Co Ltd 脂肪肝抑制剤
JPH09241206A (ja) * 1996-03-01 1997-09-16 Shionogi & Co Ltd リグナン系化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MUZZARELLI RICCARDO A.A.: "Management of hypercholesterolemia and overweight by oral administration of chitosans", BIOMED. HEALTH RES., vol. 16, 1998, pages 135 - 142, XP002948373 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009120597A (ja) * 2007-10-24 2009-06-04 Mitsubishi Tanabe Pharma Corp 非アルコール性脂肪肝炎の治療および／または予防薬
US8524212B2 (en) 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
WO2009096455A1 (ja) * 2008-01-31 2009-08-06 Astellas Pharma Inc. 脂肪性肝疾患の治療用医薬組成物
JP5302900B2 (ja) * 2008-01-31 2013-10-02 アステラス製薬株式会社 脂肪性肝疾患の治療用医薬組成物
WO2010038796A1 (ja) * 2008-09-30 2010-04-08 持田製薬株式会社 Ｃ型肝炎治療剤
JPWO2010038796A1 (ja) * 2008-09-30 2012-03-01 持田製薬株式会社 Ｃ型肝炎治療剤
US9006285B2 (en) 2008-09-30 2015-04-14 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for hepatitis C
JP2015150544A (ja) * 2014-02-19 2015-08-24 国立大学法人神戸大学 表面処理剤、表面処理ポリアミド逆浸透膜及びその製造方法

Also Published As

Publication number Publication date
CA2417492A1 (en) 2003-01-28
KR20030036658A (ko) 2003-05-09
EP1749539A2 (en) 2007-02-07
US20030153513A1 (en) 2003-08-14
AU2002224596A1 (en) 2002-02-13
EP1306094A4 (en) 2006-04-12
CN1466465A (zh) 2004-01-07
EP1306094A1 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
WO2002009815A3 (en) New pharmaceutical composition
WO2002009757A1 (en) Preventives or remedies for obesity or fatty liver
BR9916486A (pt) Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU7620200A (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU2002212739A1 (en) Compositions for forming bone or periodontium and injections for forming bone orperiodontium
AU2001284690A1 (en) Compositions exhibiting synergistic inhibition of the expression and/or activityof cyclooxygenase-2
IL152315A0 (en) Soluble ctla4 mutant molecules and pharmaceutical compositions containing the same
AUPR105400A0 (en) Processes and compositions for water treatment
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
WO2001070242A3 (en) Compositions containing molecular iodine
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
IL146789A0 (en) Amorphous nitric esters and their pharmaceutical compositions
HUP0400801A3 (en) Pharmaceutical compositions containing bile acid or bile salt fatty acid conjugates and their use
AU2003211610A1 (en) Pharmaceutical compositions for the treatment or prevention of osteoporosis
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU2001232345A1 (en) Compositions for preventing and treating digestive diseases
AU2961199A (en) Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
AU5704800A (en) Medicinal compositions for preventing or treating diarrhea
AUPR809001A0 (en) Compositions for the treatment and prevention of plant pathogens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1020037001367

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10343460

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001984401

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018162983

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2417492

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001984401

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037001367

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001984401

Country of ref document: EP